Seoul-based SeaGene, a diagnostic product maker, on Tuesday announced its NovaPlex monkeypox virus test.
The test, developed using the company’s AI-based automated test development system, can identify a positive case in 90 minutes, says Seagene.
However, for now this product is for research use only and SeaGene states that it is not yet for use in clinical diagnostic procedures. The company’s press release also did not provide any information on how accurate or sensitive the test was.
Dr. Jong-eun Chun, CEO of Seagene, said: “The outbreak of monkeypox virus shows that endemic viruses can rapidly spread to the rest of the world and is a warning that new epidemics can emerge at any time and our could put lives at risk.” Press release. “We will continue our efforts to develop products that can accurately diagnose any virus to help prevent new infectious diseases from taking hold and becoming pandemics.”
monkeypox Cases are rising around the world as part of an unprecedented outbreak of the viral disease that is usually endemic to West and Central Africa. According to the US Centers for Disease Control and Prevention, at least 4,769 cases were reported worldwide as of June 28, of which 305 were in the US.
On the same day, the Biden administration announced the first phase of a national vaccine strategy to control the spread of monkeypox, saying it would increase the number of available monkeypox vaccines to 1.6 million in the coming months.
By that time, the number of vaccines deployed was “over 9,000”, the White House said, although it said 56,000 more would be allocated immediately. Earlier this month, the U.S. 500,000. ordered Monkeypox vaccines from the smallpox/monkeypox vaccine manufacturer Bavarian Nordic.
Earlier in the week, there was little criticism of the vaccine rollout by officials in New York City, where cases rose 60 percent to 48 in just four days. The demand was so high that walk-in centers were closed Within a few hours.
“This is yet another example of a public health failure,” said New York City Council member Eric Boucher, according to NBC New York. “And given what we’re doing with COVID-19 right now, we should be more prepared.”
Testing is also part of the government’s strategy. When the outbreak began the US already had a Food and Drug Administration-sanctioned test capable of detecting monkeypox.
The White House said on Tuesday CDC Testing capacity was increased to 78 sites in 48 states. It remains to be seen whether this will be enough to meet demand.